You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.
AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
Zacks Rank #1 (Strong Buy) stocks outperform the market in both good and bad times. However, there are over 200 stocks that earn a Zacks Rank #1 at any given time...
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
biotechs: Archive
Novavax Clinches $60M Defense Contract for Coronavirus Vaccine
by Zacks Equity Research
Novavax (NVAX) secures a $60-million pact from the US Department of Defense to manufacture its COVID-19 vaccine candidate, NVX-CoV2373.
AZN MRNA NVAX EBS
biotechs
ETFs Under $20 From 5 Hottest Zones
by Sweta Killa
Let us dig into some of the ETFs that are below $20 and are from the hottest areas currently. These low-priced ETFs could lead to huge gains in the coming months.
SDIV IEZ SILJ KBWD GNOM
biotechs energy etfs finance
Gilead's Rating Upgraded on Potential Coronavirus Drug Sales
by Zacks Equity Research
Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.
GILD GSK GLPG RCUS
biotechs
Trump Picks 5 Coronavirus Vaccine Candidates Per NYT Report
by Kinjel Shah
The candidates belong to five companies, Moderna, AstraZeneca, J&J, Merck and Pfizer.
JNJ AZN PFE MRK MRNA
biotechs pharmaceuticals
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
by Sweta Jaiswal, FRM
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
GILD LLY IBB XBI BBH FBT ARKG
biotechs etfs
Will Translate Bio Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Translate Bio
TBIO
biotechs medical
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
IRWD REGN GILD ABIO NTLA PHAS
biotechs pharmaceuticals
Boost Portfolio Gains With These 6 Low Price-to-Book Stocks
by Kinjel Shah
Though price-to-earnings and price-to-sales are the first choices, P/B ratio is also a convenient tool for identifying valuable stocks.
BIIB CSIQ ADS GPK CLS VST
biotechs business-services energy
These ETF Areas Make Great Investment Choices in June
by Sweta Jaiswal, FRM
Here we highlight some ETF areas that will make interesting investment options for investors amid the coronavirus crisis.
IBB XBI BBH JETS IBUY BOTZ SKYY CLIX IRBO CLOU
airlines biotechs e-commerce etfs
4 Best ETF Charts of Q1 Earnings
by Sweta Killa
Below are four ETFs that buoyed up on strong earnings results.
MSFT IBM AMZN SPY GOOGL ITB IBUY BBC WCLD
biotechs cloud-computing construction etfs retail
Myovant Eyes Relugolix Combo Approval for Uterine Fibroids
by Zacks Equity Research
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.
JNJ ABBV MYOV TAK
biotechs
FDA Okays AVEO's NDA Filing for Treating Renal Cell Carcinoma
by Zacks Equity Research
AVEO's new drug application submission for tivozanib as a treatment of relapsed or refractory renal cell carcinoma gets acceptance from the FDA. A decision is expected on Mar 31, 2021.
AZN BMY BAYRY AVEO
biotechs
U.S. Outperforms YTD: 6 Top-Ranked ETF Winners
by Sweta Killa
Wall Street has staged a comeback since late March, leaving behind the rest of the world.
IBB QQQ JKE IGV FDN WCLD
biotechs etfs software
Gilead Down on Mixed Results From Coronavirus Drug Remdesivir
by Zacks Equity Research
Gilead's (GILD) shares decline on mixed results from a late-stage study on coronavirus drug.
ALXN RHHBY GILD INCY
biotechs
Regeneron Expands Deal With Intellia for Hemophilia Treatments
by Zacks Equity Research
Regeneron (REGN) expands partnership with Intellia Therapeutics to co-develop potential hemophilia A and B treatments.
REGN SNY GILD NTLA
biotechs
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
REGN PFE GILD MRNA LLY GSK VIR
biotechs pharmaceuticals
Implied Volatility Surging for Intec Pharma (NTEC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intec Pharma (NTEC) stock based on the movements in the options market lately.
NTEC
biotechs
Do Options Traders Know Something About Myovant (MYOV) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.
MYOV
biotechs medical
Find Strong Buy Stocks for the Coronavirus Market Rally with this Screener
by Benjamin Rains
Zacks Rank #1 (Strong Buy) stocks outperform the market in both good and bad times. However, there are over 200 stocks that earn a Zacks Rank #1 at any given time...
MRSN CODX BGS
biotechs consumer-staples retail
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
PFE MRK LLY VRTX ABBV CRSP
biotechs earnings pharmaceuticals tech-stocks
Top Stock Picks for Week of June 1, 2020
by Panel Of Zacks Experts
Two Zacks Strong Buy Stocks in Focus.
BJ LLY
biotechs retail
Buy These 5 Stocks With Impressive Sales Growth Right Away
by Swayta Shah
Sales growth can be considered by investors as a reliable metric for selecting profitable stocks amid the challenging operating backdrop.
CPB BMY INFO VST KDP
biotechs business-services consumer-staples finance medical pharmaceuticals restaurants retail utilities
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO
biotechs medical pharmaceuticals
Implied Volatility Surging for Nabriva (NBRV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
NBRV
biotechs
5 Top Stocks Up 100%+ in May With More Room to Run
by Tirthankar Chakraborty
Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."
MRK MRNA NVAX CBAY EFOI MVIS ALRN MRSN
biotechs earnings energy